On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...

SANYA, China (AP) — Rio Takeda of Japan shot a 3-under 69 on Saturday to hold a two-shot lead after three rounds of the LPGA's Blue Bay tournament on China's southern island of Hainan.

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda made it rain zebras at a Boston Celtics game Friday. The stunt saw 100 toy zebras parachute from the TD Garden arena’s rafters to represent the complex journeys of individuals with rare ...